-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on KalVista Pharmaceuticals, Raises Price Target to $32

Benzinga·01/06/2026 10:55:09
語音播報
Needham analyst Serge Belanger maintains KalVista Pharmaceuticals (NASDAQ:KALV) with a Buy and raises the price target from $28 to $32.